Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,111 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison of chemotherapy plus bevacizumab vs. chemotherapy alone as third-line treatment or beyond for advanced non-small cell lung cancer: A propensity score-matched analysis.
Hu B, Zhou X, Liu Y, Li Q, Xiang M, Zou B, Peng F, Huang M, Gong Y, Zhu J, Wang Y, Ren L, Xu Y, Zhang Y, Li Y, Yu M, Xue J, Deng L, Wang J, Ding Z, Lu Y. Hu B, et al. Among authors: zou b. Oncol Lett. 2018 Apr;15(4):5671-5679. doi: 10.3892/ol.2018.8064. Epub 2018 Feb 15. Oncol Lett. 2018. PMID: 29556304 Free PMC article.
Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer.
Lu Y, Xue J, Deng T, Zhou X, Yu K, Deng L, Huang M, Yi X, Liang M, Wang Y, Shen H, Tong R, Wang W, Li L, Song J, Li J, Su X, Ding Z, Gong Y, Zhu J, Wang Y, Zou B, Zhang Y, Li Y, Zhou L, Liu Y, Yu M, Wang Y, Zhang X, Yin L, Xia X, Zeng Y, Zhou Q, Ying B, Chen C, Wei Y, Li W, Mok T. Lu Y, et al. Among authors: zou b. Nat Med. 2020 May;26(5):732-740. doi: 10.1038/s41591-020-0840-5. Epub 2020 Apr 27. Nat Med. 2020. PMID: 32341578 Clinical Trial.
Publisher Correction: Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer.
Lu Y, Xue J, Deng T, Zhou X, Yu K, Deng L, Huang M, Yi X, Liang M, Wang Y, Shen H, Tong R, Wang W, Li L, Song J, Li J, Su X, Ding Z, Gong Y, Zhu J, Wang Y, Zou B, Zhang Y, Li Y, Zhou L, Liu Y, Yu M, Wang Y, Zhang X, Yin L, Xia X, Zeng Y, Zhou Q, Ying B, Chen C, Wei Y, Li W, Mok T. Lu Y, et al. Among authors: zou b. Nat Med. 2020 Jul;26(7):1149. doi: 10.1038/s41591-020-0973-6. Nat Med. 2020. PMID: 32555427
Applicability of the adjusted graded prognostic assessment for lung cancer with brain metastases using molecular markers (Lung-molGPA) in a Chinese cohort: A retrospective study of multiple institutions.
Zhang T, Zhang Y, Zhou L, Deng S, Huang M, Liu Y, Liu Y, Gong Y, Zhu J, Xue J, Bai Y, Ma H, Zhang Y, Yu M, Li Y, Wang Y, Zou B, Zhou X, Xiu W, Na F, Xu Y, Peng F, Wang J, Lu Y. Zhang T, et al. Among authors: zou b. Cancer Med. 2020 Dec;9(23):8772-8781. doi: 10.1002/cam4.3485. Epub 2020 Oct 7. Cancer Med. 2020. PMID: 33027555 Free PMC article.
Stereotactic body radiotherapy to the primary lung lesion improves the survival of the selected patients with non-oligometastatic NSCLC harboring EGFR activating mutation with first-line EGFR-TKIs: a real-world study.
Wei H, Zhou X, Yang H, Gong Y, Wang J, Xu Y, Zhou L, Xue J, Zou B, Zhang Y, Zhu J, Peng F, Huang M, Lu Y, Liu Y. Wei H, et al. Among authors: zou b. J Cancer Res Clin Oncol. 2022 Oct;148(10):2589-2598. doi: 10.1007/s00432-021-03831-z. Epub 2021 Oct 20. J Cancer Res Clin Oncol. 2022. PMID: 34669037
[Radiation-Induced Heart Disease: Current Status and Challenges].
Yang HJ, Zhang Y, Peng O, Zou BW. Yang HJ, et al. Sichuan Da Xue Xue Bao Yi Xue Ban. 2022 Nov;53(6):1127-1134. doi: 10.12182/20221160302. Sichuan Da Xue Xue Bao Yi Xue Ban. 2022. PMID: 36443063 Free PMC article. Review. Chinese.
2,111 results